Waylis Therap Company Profile
✉ Email this page to a colleague
What is the competitive landscape for WAYLIS THERAP, and when can generic versions of WAYLIS THERAP drugs launch?
WAYLIS THERAP has eleven approved drugs.
There is one US patent protecting WAYLIS THERAP drugs.
There are twenty-four patent family members on WAYLIS THERAP drugs in fourteen countries and five supplementary protection certificates in four countries.
Summary for Waylis Therap
International Patents: | 24 |
US Patents: | 1 |
Tradenames: | 11 |
Ingredients: | 11 |
NDAs: | 11 |
Drugs and US Patents for Waylis Therap
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Waylis Therap | COREG | carvedilol | TABLET;ORAL | 020297-003 | Sep 14, 1995 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Waylis Therap | AVODART | dutasteride | CAPSULE;ORAL | 021319-001 | Nov 20, 2001 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
Waylis Therap | VALIUM | diazepam | TABLET;ORAL | 013263-002 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Waylis Therap
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Waylis Therap | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-004 | Oct 20, 2006 | 5,760,069*PED | ⤷ Sign Up |
Waylis Therap | COREG | carvedilol | TABLET;ORAL | 020297-004 | May 29, 1997 | 4,503,067*PED | ⤷ Sign Up |
Waylis Therap | JALYN | dutasteride; tamsulosin hydrochloride | CAPSULE;ORAL | 022460-001 | Jun 14, 2010 | 5,998,427 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for WAYLIS THERAP drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Extended-release Capsules | 40 mg | ➤ Subscribe | 2007-12-21 |
➤ Subscribe | Capsules | 0.5 mg | ➤ Subscribe | 2007-10-29 |
➤ Subscribe | Tablets | 1 mg, 2 mg and 3 mg | ➤ Subscribe | 2008-12-15 |
➤ Subscribe | Extended-release Capsules | 10 mg and 20 mg | ➤ Subscribe | 2008-03-18 |
➤ Subscribe | Extended-release Capsules | 80 mg | ➤ Subscribe | 2007-11-19 |
➤ Subscribe | Capsule | 0.5 mg/0.4 mg | ➤ Subscribe | 2010-10-26 |
International Patents for Waylis Therap Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 1434572 | ⤷ Sign Up |
Canada | 2463134 | ⤷ Sign Up |
Japan | 2007532689 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Waylis Therap Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0719278 | 03C0030 | France | ⤷ Sign Up | PRODUCT NAME: DUTASTERIDE; NAT. REGISTRATION NO/DATE: NL 28 131 20030327; FIRST REGISTRATION: SE - 17 871 20020719 |
0268956 | 1999C0030 | Belgium | ⤷ Sign Up | PRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508 |
0719278 | SPC/GB03/018 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: DUTASTERIDE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SOLVATE.; REGISTERED: SE 17871 20020719; SE 17872 20020719; UK PL 19494/0005 20030117; UK PL 19494/0006 20030117 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.